TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01885065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gel-based artificial saliva
Description: Gel-based artificial saliva is an edible non-nutritious gel intended to relieve dry mouth.~Taking orally 1-2 teaspoon each time, 5 times / day (30-50 ml/ day) for four weeks.
Study: NCT04425317

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood sample
Description: Blood sample and endometrial biopsy on the moment of oocyte retrieval
Study: NCT03415178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab SAR236553
Description: Pharmaceutical form: Solution for injection Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab SAR236553
Description: Pharmaceutical form: Solution for injection Route of administration: Subcutaneous

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Current auto-injector device (AI)
Description: Pharmaceutical form:~Route of administration: Subcutaneous self-administration of alirocumab

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New auto-injector device (SYDNEY)
Description: Pharmaceutical form:~Route of administration: Subcutaneous self-administration of alirocumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT01978756

Intervention type: OTHER
Intervention: Outpatient clinic
Description: The participants are seen at the outpatient clinic by a physician or a physician assistant. To analyse fibrosis clinical examination of the breast will be performed. To analyse shoulder function anteversion / retroversion, abduction / adduction and internal / external rotation will be measured. To analyse edema the arm circumference will be measured 15 cm above and below the medial epicondyle (both sides). Also, a photograph of the breast will be made for cosmetic analysis using standardized procedures. Finally a blood sample or saliva will be obtained, if the patient has given written informed consent to participate in the Biobank.
Study: NCT02587936

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborative Model of Primary care and Subspecialty care
Description: Pieces will access Electronic Health Record for all patients receiving care at the participating sites to detect patients with a triad of chronic kidney disease, diabetes and hypertension, facilitate management and monitor outcomes. To maximize successful implementation of care, a Practice Facilitator will be at each site with standardized role training using a curriculum based on the Agency for Healthcare Research and Quality (AHRQ) Practice Facilitation Handbook. Specific interventions are maintaining BP less than 140/90 mmHg, use of angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), treatment with statins, aiming for glycosylated Hemoglobin (HgA1C) at the recommended target, and avoiding nephrotoxic medications. Additional interventions include chronic kidney disease education for Primary Care Providers (PCP) and patients using National Kidney Disease Education Program (NKDEP) materials.
Study: NCT03573297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine capsules, oral administration, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine capsules, oral administration, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine capsules, oral administration, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules, oral administration, once daily
Study: NCT02078817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: IV infusions of 0.5mg/kg of Ketamine hydrochloride over a 40-minute infusion period. Participants will receive a total of 6 doses over a 2-week period.
Study: NCT02943213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorpromazine Hydrochloride
Description: Chlorpromazine Hydrochloride (25 mg Tablet) - Generic US Applicant holder is USL Pharma Inc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorpromazine Hydrochloride
Description: Chlorpromazine Hydrochloride (25 mg Tablet) - Generic US Applicant holder is USL Pharma Inc.
Study: NCT00700635

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate
Description: 0.5 mL, 2 doses Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate
Description: 0.5 mL, 2 doses Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate
Description: 0.5 mL, 1 dose Intramuscular
Study: NCT02552940

Intervention type: DRUG
Intervention: Tocilizumab
Description: Participants with RA receive TCZ SC, as per routine clinical practice and are followed for approximately 6 months.
Study: NCT02366416

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Physical activity
Study: NCT00193908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cavilon (TM) Durable Barrier Cream
Description: Cavilon (TM) Durable Barrier Cream will be applied to either the medial or the lateral side of the treated breast. Side will depend on randomisation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cavilon (TM) Durable Barrier Cream
Description: Cavilon (TM) Durable Barrier Cream will be applied to either the medial or the lateral side of the treated breast. Side will depend on randomisation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorbolene
Description: Sorbolene will be applied to either the medial or the lateral side of the treated breast. Side will be determined by randomisation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorbolene
Description: Sorbolene will be applied to either the medial or the lateral side of the treated breast. Side will be determined by randomisation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Minimum prescribed dose to the chest wall is 45Gy in 25 fractions. Planning and Treatment is per the study protocol

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Minimum prescribed dose to the chest wall is 45Gy in 25 fractions. Planning and Treatment is per the study protocol
Study: NCT02676804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity, aerobic exercise.
Description: Aerobic exercise will blend unsupervised moderate and supervised high intensity exercise. It will consist of walking/jogging modalities, dependent on the subject's level of bradykinesia, paced by the subject's level of perceived exertion. The exercise protocol will be designed to target an total of at least 150 minutes of cardio exercise per week.~Exercise training will be performed 5 times per week for 6 weeks, consisting of 3 supervised high intensity sessions and 2 at home moderate intensity sessions. High intensity sessions will be performed on a treadmill at an intensity rating of \~ 15 and 17 on a rating of perceived exertion (RPE) scale of 6 to 20. The moderate intensity exercise will target an RPE of \~10 - 12 and participants will be asked to complete this on their own.
Study: NCT00988780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maraviroc
Description: Maraviroc 600mg po BID every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Efavirenz 600 mg qd every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Tenofovir/Emtricitabine 300/200 mg qd from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets po BID every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Efavirenz 600 mg qd every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Tenofovir/Emtricitabine 300/200 mg qd from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.
Study: NCT04480528

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Training (BFRT)
Description: A pressurized cuff is applied to the proximal thigh in order to partially occlude blood flow as the patient exercises.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Blood Flow Restriction Training (Sham BFRT)
Description: A minimally pressurized cuff is applied to the proximal thigh in order to mimic the active blood flow restriction unit as the patient exercises.
Study: NCT01831843

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Group C
Description: non-heated, non-humidified conventional breathing circuit was used in group C patient

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group E
Description: breathing tube which apply humidity and heat (Evaqua™ Breathing Circuits manufactured by Fischer \& Paykel)was used in group E patient

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group M
Description: Heated humid tube with a warming device (Mega Acer kit manufactured by Acemedical,Seoul Korea)was used in group M patient
Study: NCT04005768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulphate
Description: After a stabilization period of 20 min and 10 min after the first blood collection, Plaquenil (Hydroxychloroquine sulfate) will be administered per os (total dose of 400 mg) in a randomized, double-blinded fashion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After a stabilization period of 20 min and 10 min after the first blood collection, Placebo will be administered per os (2 tablets) in a randomized, double-blinded fashion.
Study: NCT04291040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Following randomization, participants will independently view the multimedia based decision aid on a provided tablet. They will also receive provider counseling. For the remainder of the pregnancy, they will receive a text message with a link to the multimedia based presentation. This will occur every 4 weeks until 12 weeks postpartum.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Description: The control arm will receive routine prenatal care including provider counselling on postpartum contraceptive options.
Study: NCT01173172

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Boron Neutron Capture Therapy
Description: Boronophenylalanine (BPA) 500 mg/kg on D1 and D30 followed by BNCT for 2 fractions (D1 and D30)
Study: NCT01953991

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dentures
Description: Removable prosthesis to replace missing teeth

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dentures
Description: Removable prosthesis to replace missing teeth
Study: NCT04019639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: application of CG Paste+EasyFoam
Description: Prior to application of CG paste, sharp debridement can be performed first in the operating room under local anesthesia or general anesthesia. After this, hemostasis is performed by an electrocoagulator and the medical device is applied to the affected area. During the procedure, remove the packaging material and remove the syringe to remove the protective cap in front of the syringe. Slowly push the syringe plunger and apply the contents to the area where you want to use. Depending on the location and size of the wound area, an injection cap can be used. Apply CG paste and apply Easyfoam to finish the dressing.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: application of EasyFoam
Description: Prior to applying EasyFoam, sharp debridement can be performed first in the operating room under local anesthesia or general anesthesia. Marginal resection is performed until the necrotic tissue is removed sufficiently and pin point bleeding is seen on the wound. After that, hemostasis is done with an electrocoagulator and EasyFoam is applied to the affected area.
Study: NCT01044524

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SLV 334
Description: 2000 mg via i.v. solution
Study: NCT04262219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iShare
Description: The iShare intervention consists of a two-episode educational podcast series containing information about breast cancer patients' sexual problems, approaches for addressing sexual concerns, and information about discussing sexual concerns with patients, such as initiating a conversation about sexual health and asking questions to assess sexual concern. Both episodes feature expert guests and relevant discussions or case studies.
Study: NCT00945737

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy protein; 25 grams/day
Description: Soy protein

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control protein
Description: Milk protein
Study: NCT04021433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Repeated doses of IM/SC ketamine up to 3 times a week
Study: NCT02582489

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate Concentrate
Description: Subjects undergoing autologous bone marrow aspirate concentrate will receive an intra-articular injection into the affected knee.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Meniscectomy
Description: All subjects will undergo either a partial or complete meniscectomy to treat the torn meniscus.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard Meniscectomy
Description: All subjects will undergo either a partial or complete meniscectomy to treat the torn meniscus.
Study: NCT01341704

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSP3-LSP/AlOH
Description: 30 µg of test vaccine MSP3-LSP/AlOH, administered by subcutaneous route according to the following schedule:- Primary administration: Three doses administered at 4 weeks interval: D0, D28 (± 2 days), D56 (± 4 days)~Secondary administration (Boost):~Year 1: One dose 3 months after the third dose Year 2: Two doses, given exactly one year after the date corresponding to the third dose and the first boost given during Year 1

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Verorab Vaccine
Description: The Verorab rabies vaccine will be given as control for the primary series of the experimental vaccine. It consists of inactivated rabies virus produced in vero cells (Wistar Rabies PM/W138 1503-3M (inactivated). Manufacturer SANOFI PASTEUR SA. Presentation is 0.5 ml per dose in a pre-filled syringe.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl/Normal Saline
Description: 0.5 ml per dose; to be given as control for the secondary/booster doses of experimental vaccine
Study: NCT00976365

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: THL-P
Description: 20ml/bottle, TID, 24weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: THL-P
Description: 20ml/bottle, TID, 24weeks
Study: NCT00352118

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: subcutaneously on Days 5-14, repeating every 3 weeks for 2 courses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: If applicable on day 5, repeating every 3 weeks for 2 courses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Intravenous over 1 hour on day 1, every 3 weeks for 3 courses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Intravenous over 1 hour on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Intravenous continuously on days 1-4.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: As appropriate, neck dissection.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 60 Gy 5 days/week x 6 weeks with cisplatin
Study: NCT00729742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: erlotinib + dalotuzumab
Description: Part II: All patients will receive 1 week of erlotinib 150 mg tablets per day.~Arm 1: Patients who experience a PET response will continue on erlotinib monotherapy until disease progression.~Arm 2: Patients who fail to receive a PET response will continue to take erlotinib in combination with dalotuzumab 10 mg/kg IV infusion once weekly. At the time of disease progression, patients on erlotinib monotherapy will be offered to crossover to dalotuzumab 10 mg/kg IV infusion once weekly in combination with erlotinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: erlotinib monotherapy
Description: Part I: All patients will receive erlotinib 150 mg tablets per day until disease progression.
Study: NCT02349412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early palliative care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early palliative care
Study: NCT03427892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Brexpiprazole is an atypical antipsychotic drug that is used to treat mental/mood disorders.
Study: NCT01029756

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh Laryngoscope
Description: Device used to gain a direct view of the vocal cords, to enable an endotracheal tube to be passed into the trachea at induction of anaesthesia.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pentax AWS Videolaryngoscope
Description: Self-contained video laryngoscope with an integral colour-viewing screen mounted on the handle. A camera at the tip transmits an indirect image, which obviates the need to obtain a direct view of the vocal cords, when passing an endotracheal tube on induction of anaesthesia.
Study: NCT00737178

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CuT380A
Description: Comparison of different timing of IUD insertion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CuT380A
Description: Comparison of different timing of IUD insertion
Study: NCT00587067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOXURIDINE
Description: \[0.16\* mg/kg/day X 30 ml\] / pump flow rate~\* If the patient is \>25% above ideal body weight, the dose of FUDR will be calculated from an average of the patients actual and ideal body weights. For example, for a patient who is 5ft. 10 inches and weighs 100kg: Ideal Body Weight (kg) = 50 + (2.3 X height in inches over 5 feet) = 50 + (2.3 X 10) = 73 Weight Used for dose calculation = (100 + 73)/2 = 86.5 Therefore, FUDR Dose will be = (0.16 X 86.5 X 30)/Flow Rate If no dose modification due to toxicity is required, the dosages given above (adjusted for changes in weight and pump flow rate) will be repeated on Day 1 of Week 1 of Cycle 2 and all subsequent cycles.
Study: NCT04269616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Order of pictographs provided to participants
Description: The pictographs presented to participants about survival and disability were varied in the order in which they were presented (i.e. survival or disability information first).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Order of pictographs provided to participants
Description: The pictographs presented to participants about survival and disability were varied in the order in which they were presented (i.e. survival or disability information first).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Order of pictographs provided to participants
Description: The pictographs presented to participants about survival and disability were varied in the order in which they were presented (i.e. survival or disability information first).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Order of pictographs provided to participants
Description: The pictographs presented to participants about survival and disability were varied in the order in which they were presented (i.e. survival or disability information first).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Level of description in survival pictograph
Description: The pictographs presented to participants about survival and disability were varied in the level of description provided in the survival pictograph (i.e. only numerical data, or also a description of course of NICU stay).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Level of description in survival pictograph
Description: The pictographs presented to participants about survival and disability were varied in the level of description provided in the survival pictograph (i.e. only numerical data, or also a description of course of NICU stay).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Level of description in survival pictograph
Description: The pictographs presented to participants about survival and disability were varied in the level of description provided in the survival pictograph (i.e. only numerical data, or also a description of course of NICU stay).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Level of description in survival pictograph
Description: The pictographs presented to participants about survival and disability were varied in the level of description provided in the survival pictograph (i.e. only numerical data, or also a description of course of NICU stay).